Abstract
VCP/p97/Cdc48, a member of the ATPases associated with diverse cellular activities (AAA) family, is necessary for the endoplasmic-reticulum-associated protein degradation (ERAD) pathway to maintain protein homeostasis. Overwhelming proteotoxic stress drove cancer cells to enhance VCP/p97/Cdc48-associated ERAD to maintain protein homeostasis for survival, demonstrating that VCP/p97/Cdc48 expression was positively correlated with cancer prognosis. More studies revealed that targeting VCP/p97/Cdc48 could be a potential target in cancer therapy. CB-5083, a novel inhibitor of VCP/p97/Cdc48, is in clinical trials as the first VCP/p97/Cdc48- inhibiting drug for cancer therapy. Here, we discuss the relationship between VCP/p97/Cdc48, ERAD, protein homeostasis and cancer therapy.
Keywords: VCP/p97/Cdc48, protein homeostasis, ERAD, cancer therapy, ER stress, CB-5083.
Current Molecular Medicine
Title:VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy
Volume: 17 Issue: 9
Author(s): B. Lan, S. Chai, P. Wang*K. Wang*
Affiliation:
- Department of Respiratory Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,China
- Department of Respiratory Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,China
Keywords: VCP/p97/Cdc48, protein homeostasis, ERAD, cancer therapy, ER stress, CB-5083.
Abstract: VCP/p97/Cdc48, a member of the ATPases associated with diverse cellular activities (AAA) family, is necessary for the endoplasmic-reticulum-associated protein degradation (ERAD) pathway to maintain protein homeostasis. Overwhelming proteotoxic stress drove cancer cells to enhance VCP/p97/Cdc48-associated ERAD to maintain protein homeostasis for survival, demonstrating that VCP/p97/Cdc48 expression was positively correlated with cancer prognosis. More studies revealed that targeting VCP/p97/Cdc48 could be a potential target in cancer therapy. CB-5083, a novel inhibitor of VCP/p97/Cdc48, is in clinical trials as the first VCP/p97/Cdc48- inhibiting drug for cancer therapy. Here, we discuss the relationship between VCP/p97/Cdc48, ERAD, protein homeostasis and cancer therapy.
Export Options
About this article
Cite this article as:
Lan B., Chai S. , Wang P. *, Wang K.*, VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy, Current Molecular Medicine 2017; 17 (9) . https://dx.doi.org/10.2174/1566524018666180308111238
DOI https://dx.doi.org/10.2174/1566524018666180308111238 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prediction and Analysis of Hub Genes in Renal Cell Carcinoma based on CFS Gene Selection Method Combined with Adaboost Algorithm
Medicinal Chemistry Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Beyond the "Lock and Key" Paradigm: Targeting Lipid Rafts to Induce the Selective Apoptosis of Cancer Cells
Current Medicinal Chemistry A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity
Current Genomics Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Angiogenesis and the Heart
Recent Patents on Cardiovascular Drug Discovery Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy Recurrent Hepatitis C After Liver Transplantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bombesin-like Peptides: Candidates as Diagnostic and Therapeutic Tools
Current Pharmaceutical Design Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Biodistribution and Tumor Targeting of Indium and Iodine-labeled Shiga Toxin B-Subunit
Current Radiopharmaceuticals Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease
Current Pharmaceutical Design Antioxidant Therapy and Drugs Interfering with Lipid Metabolism: Could They Be Effective in NAFLD Patients?
Current Pharmaceutical Design The Role of Antiangiogenetic Agents in the Treatment of Breast Cancer
Current Medicinal Chemistry Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets Mitochondrial Biogenesis: Regulation By Endogenous Gases During Inflammation and Organ Stress
Current Pharmaceutical Design